timothy sykes logo
HROW Stock Rips Higher As Traders Digest Mixed Quarter Thumbnail
G Google News

HROW Stock Rips Higher As Traders Digest Mixed Quarter

JACK KELLOGG•UPDATED JUN. 10, 2026, 5:04 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Harrow Inc Com stocks have been trading up by 9.8 percent after bullish sentiment on its latest strategic growth initiatives.

Key Takeaways

  • Harrow posted a wider Q1 loss with EPS of -$0.74 versus -$0.50 a year ago, and revenue fell to $44.2M from $47.83M on an $8M VEVYE-related adjustment.
  • Management reiterated confidence in full-year goals and expects to benefit from improved VEVYE reimbursement starting in Q2 2026, framing Q1 as a reset, not a collapse.
  • Cantor Fitzgerald trimmed its Harrow price target from $91 to $88 but kept an Overweight rating, signaling continued bullish longer-term expectations.
  • B. Riley cut its Harrow target from $65 to $60 yet reaffirmed a Buy rating, pointing to VEVYE pricing pressure but strong prescription trends and product catalysts.
  • Insider buying popped up as Harrow’s CEO and CFO bought roughly $302,000 and $105,000 of stock on 2026/05/14, a visible vote of confidence.

Candlestick Chart

Live Update At 17:03:34 EDT: On Wednesday, June 10, 2026 Harrow Inc Com stock [NASDAQ: HROW] is trending up by 9.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Harrow Inc Com, ticker HROW, is trading like a battleground story after a messy quarter. On the tape, HROW just closed near $35.90 after touching $37.64 intraday, a strong push from the prior day’s $33.46 close. Over the last few weeks, HROW has stair-stepped from the low-$30s into the mid-$30s, with multiple sessions holding above $34. That tells traders dip buyers have been active.

Intraday action shows steady accumulation. From the open around $33.52, HROW pushed into the mid-$37s with shallow pullbacks and tight five‑minute candles. That’s classic trending behavior, not random chop, hinting at strong demand chasing the news.

More Breaking News

Fundamentally, the latest reported quarter showed revenue of $44.2M and a net loss of about $27.6M, or EPS of -$0.74. Gross margin is high at 74.1%, but leverage is heavy: long‑term debt sits near $300M and interest coverage is thin at 1.5 times. HROW carries a rich price-to-sales ratio around 5.6 and a tiny book value base, which means the stock trades more on growth expectations than current profits. For active traders, that combination often fuels sharp moves both ways when sentiment shifts.

Why Traders Are Watching HROW Now

The market’s focus on HROW right now starts with that Q1 print. Harrow reported revenue slipping from $47.83M to $44.2M year over year, while EPS fell from -$0.50 to -$0.74. On the surface, that looks ugly. But management pinned much of the damage on an $8M gross‑to‑net adjustment tied to new commercial coverage for VEVYE, its dry eye product. In plain English, HROW took a one‑time accounting and reimbursement hit to get better coverage in place.

For traders, this is a classic “near‑term pain, potential long‑term gain” setup. HROW leadership says underlying demand is strong, they reiterated full‑year financial goals, and they expect improved reimbursement on VEVYE to help numbers as soon as Q2 2026. That’s the kind of forward guidance momentum traders watch closely — if the chart starts to confirm, sentiment can flip fast.

Wall Street is leaning that way. Cantor Fitzgerald shaved its Harrow price target from $91 to $88 but kept an Overweight rating. B. Riley trimmed from $65 to $60 and still calls HROW a Buy, citing weaker near‑term VEVYE pricing and tempered growth, but highlighting strong prescription volume, momentum in IHEEZO and Triesence, and upcoming product and coding catalysts in the back half of the year. Across the Street, Harrow holds an overall Buy consensus with an average target of about $68.38, well above current levels.

Add insider buying to the mix. On 2026/05/14, HROW disclosed that its CEO bought 10,000 shares (around $302,000) and its CFO picked up 3,500 shares (roughly $105,000). A separate filing shows CEO Mark L. Baum now directly owns about 2.996M shares. When top brass steps in after a rough quarter, traders read that as a clear confidence signal.

Conclusion

For active traders, HROW is a clean example of how messy fundamentals can still drive powerful trading setups. The company just printed a wider loss, saw revenue dip, and absorbed an $8M VEVYE adjustment. On paper, that’s not pretty. Yet HROW’s chart is pushing higher, analysts mostly remain in the Buy camp with price targets far above the current quote, and insiders are putting fresh cash to work.

That tension — bad backward-looking numbers vs. supportive forward-looking signals — is what creates opportunity. HROW is leveraged, unprofitable, and priced for growth, so it will not trade like a sleepy value name. Any confirmation that VEVYE reimbursement is improving, or that IHEEZO and Triesence are ramping as B. Riley expects, can keep the squeeze going. On the flip side, if those catalysts slip, the same leverage that helps on the way up can hurt on the way down.

Traders following Harrow Inc Com should focus on price action first, then line it up with the next few quarters of VEVYE and procedure‑driven revenue. As Tim Sykes likes to say, “The market doesn’t care about your opinion, it cares about price action — react to what the chart and news actually show, not what you wish would happen.” That mindset goes hand in hand with disciplined execution; as millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. For HROW, that means respecting the current uptrend while staying ready to cut losses fast if the story shifts. This article is for educational and research purposes only and is not trading advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading HROW

Millionaire's
POV on HROW

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”